These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 9834251)
21. Glycosylphosphatidylinositol (GPI)-anchored membrane proteins in clinical pathophysiology of paroxysmal nocturnal hemoglobinuria (PNH). Shichishima T Fukushima J Med Sci; 1995 Jun; 41(1):1-13. PubMed ID: 8606038 [TBL] [Abstract][Full Text] [Related]
22. Flow cytometric analysis of CD55 and CD59 expression on blood cells in paroxysmal nocturnal haemoglobinuria. Dworacki G; Sikora J; Mizera-Nyczak E; Trybus M; Mozer-Lisewska I; Czyz A; Zeromski J Folia Histochem Cytobiol; 2005; 43(2):117-20. PubMed ID: 16044949 [TBL] [Abstract][Full Text] [Related]
23. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Ferreira VP; Pangburn MK Blood; 2007 Sep; 110(6):2190-2. PubMed ID: 17554058 [TBL] [Abstract][Full Text] [Related]
24. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Hill A; Ridley SH; Esser D; Oldroyd RG; Cullen MJ; Kareclas P; Gallagher S; Smith GP; Richards SJ; White J; Smith RA; Hillmen P Blood; 2006 Mar; 107(5):2131-7. PubMed ID: 16322479 [TBL] [Abstract][Full Text] [Related]
25. Paroxysmal nocturnal hemoglobinuria in children. van den Heuvel-Eibrink MM Paediatr Drugs; 2007; 9(1):11-6. PubMed ID: 17291133 [TBL] [Abstract][Full Text] [Related]
26. The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon. Asimakopoulos JV; Terpos E; Papageorgiou L; Kampouropoulou O; Christoulas D; Giakoumis A; Samarkos M; Vaiopoulos G; Konstantopoulos K; Angelopoulou MK; Vassilakopoulos TP; Meletis J Med Sci Monit; 2014 Jan; 20():123-39. PubMed ID: 24463881 [TBL] [Abstract][Full Text] [Related]
27. Decay-accelerating factor (CD55) and membrane inhibitor of reactive lysis (CD59) are released within exosomes during In vitro maturation of reticulocytes. Rabesandratana H; Toutant JP; Reggio H; Vidal M Blood; 1998 Apr; 91(7):2573-80. PubMed ID: 9516159 [TBL] [Abstract][Full Text] [Related]
28. [Protection of PNH red blood cells from lysis by transferring GPI-anchored protein vesicles of normal human RBCs in vitro]. Yang Y; Xu C; Pan H Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Aug; 21(4):278-81. PubMed ID: 12567450 [TBL] [Abstract][Full Text] [Related]
29. CD71 improves delineation of PNH type III, PNH type II, and normal immature RBCS in patients with paroxysmal nocturnal hemoglobinuria. Sutherland DR; Richards SJ; Ortiz F; Nayyar R; Benko M; Marinov I; Illingworth A Cytometry B Clin Cytom; 2020 Mar; 98(2):179-192. PubMed ID: 31705743 [TBL] [Abstract][Full Text] [Related]
31. Value of CD16/CD66b/CD45 in comparison to CD55/CD59/CD45 in diagnosis of paroxysmal nocturnal haemoglobinuria: An Indian experience. Kotru M; Sharma R; Pramanik SK; Purohit A; Singh G; Singh AK; Muterja D; Mishra P; Seth T; Tyagi S; Mahapatra M; Pati HP; Saxena R Indian J Med Res; 2017 Sep; 146(3):362-368. PubMed ID: 29355143 [TBL] [Abstract][Full Text] [Related]
32. Correction of the PNH defect by GPI protein transfer: still an open question. Bütikofer P Blood; 2000 Mar; 95(5):1876-8. PubMed ID: 10744388 [No Abstract] [Full Text] [Related]
33. Immunophenotypic discrepancies between granulocytic and erythroid lineages in peripheral blood of patients with paroxysmal nocturnal haemoglobinuria. Pakdeesuwan K; Wanachiwanawin W; Siripanyaphinyo U; Pattanapanyasat K; Wilairat P; Issaragrisil S Eur J Haematol; 2000 Jul; 65(1):8-16. PubMed ID: 10914934 [TBL] [Abstract][Full Text] [Related]
34. Expression of recombinant transmembrane CD59 in paroxysmal nocturnal hemoglobinuria B cells confers resistance to human complement. Rother RP; Rollins SA; Mennone J; Chodera A; Fidel SA; Bessler M; Hillmen P; Squinto SP Blood; 1994 Oct; 84(8):2604-11. PubMed ID: 7522635 [TBL] [Abstract][Full Text] [Related]
35. Aplastic anemia and paroxysmal nocturnal hemoglobinuria: search for a pathogenetic link. Griscelli-Bennaceur A; Gluckman E; Scrobohaci ML; Jonveaux P; Vu T; Bazarbachi A; Carosella ED; Sigaux F; Socié G Blood; 1995 Mar; 85(5):1354-63. PubMed ID: 7858265 [TBL] [Abstract][Full Text] [Related]
36. Oxidative status of red blood cells, neutrophils, and platelets in paroxysmal nocturnal hemoglobinuria. Amer J; Zelig O; Fibach E Exp Hematol; 2008 Apr; 36(4):369-77. PubMed ID: 18261835 [TBL] [Abstract][Full Text] [Related]
37. Aplastic anaemia and paroxysmal nocturnal haemoglobinuria: a study of the GPI-anchored proteins on human platelets. Vu T; Griscelli-Bennaceur A; Gluckman E; Sigaux F; Carosella ED; Menier C; Scrobohaci ML; Socié G Br J Haematol; 1996 Jun; 93(3):586-9. PubMed ID: 8652377 [TBL] [Abstract][Full Text] [Related]
38. Longer in vivo survival of CD59- and decay-accelerating factor-almost normal positive and partly positive erythrocytes in paroxysmal nocturnal hemoglobinuria as compared with negative erythrocytes: a demonstration by differential centrifugation and flow cytometry. Fujioka S; Yamada T Blood; 1992 Apr; 79(7):1842-5. PubMed ID: 1373090 [TBL] [Abstract][Full Text] [Related]